What is Gilteritinib?

What is Gilteritinib?

Gilteritinib (generic name: gilteritinib) works in a fundamentally different way from traditional chemotherapy. Traditional chemotherapy fights cancer by killing rapidly dividing cells, but this approach also damages other normal cells in the body, leading to many side effects. Gilteritinib, however, is a targeted therapy. It specifically targets the FLT3 mutation — a key driver of leukemia cell proliferation. By precisely inhibiting the FLT3 mutation, gilteritinib can stop leukemia cells from growing in the bone marrow, thereby making room for healthy red blood cells, white blood cells, and platelets to recover. For patients with FLT3 mutation‑positive relapsed or refractory AML, gilteritinib is the only targeted therapy approved by the U.S. FDA.

How effective is Gilteritinib?

A pivotal clinical study enrolled patients with FLT3m+ AML whose disease had relapsed or not improved after prior treatment, and directly compared overall survival between gilteritinib and chemotherapy. The results showed that the median overall survival for patients taking gilteritinib was 9 months, compared to only 6 months for those receiving chemotherapy. Here, "median" refers to the middle value in a set of numbers, not the average; "overall survival" means the length of time a patient lives from the start of treatment. Although individual results may vary, these data indicate that gilteritinib has the potential to help patients live longer. Doctors will explain what these numbers mean for each patient’s specific situation.

Complete remission and reduced transfusion dependence

Beyond extending survival, the study also used other measures to assess gilteritinib’s effectiveness, one of which is "complete remission." Complete remission means that no signs of leukemia cells can be detected in the blood and bone marrow, and blood cell counts have returned to normal — of course, this does not mean the cancer is cured. Additionally, gilteritinib helped some patients reduce their need for transfusions. Among patients who required transfusions at the start of the study, one out of every three (68 out of 197 people) achieved a transfusion‑free state lasting up to 8 weeks after receiving gilteritinib. This significantly reduces the burden of repeated transfusions and improves quality of life.